PTC Therapeutics, Inc.
PTCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001070081
In the last 90 days, PTC Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 384 institutions reported holding it in 13F filings for Q2 2026, worth $8.20B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:16 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M |
| Operating expenses | $863.7M | $1.11B | $1.38B | $1.15B | $913.0M |
| Research and development | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M |
| Selling, general and administrative | $347.1M | $300.9M | $332.5M | $326.0M | $285.8M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M |
| Income tax | $14.0M | $176.0K | -$69.5M | -$28.5M | $5.56M |
| Net income | $682.6M | -$363.3M | -$626.6M | -$559.0M | -$523.9M |
| EPS, basic | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| EPS, diluted | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Weighted shares, basic | 79.5M | 76.8M | 74.8M | 71.7M | 70.5M |
| Weighted shares, diluted | 88.3M | 76.8M | 74.8M | 71.7M | 70.5M |
| Margins and growth | |||||
| Operating margin | 50.1% | -37.5% | -46.9% | -64.0% | -69.5% |
| Net margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% |
| Revenue growth, year over year | +114.5% | −14.0% | +34.2% | +29.7% | +41.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $984.6M | $779.7M | $594.0M | $279.8M | $189.7M |
| Short-term investments | $960.7M | $360.0M | $282.7M | $130.9M | $583.7M |
| Accounts receivable | $181.6M | $158.6M | $160.8M | $155.6M | $110.5M |
| Inventory | $79.6M | $23.2M | $30.6M | $21.8M | $15.9M |
| Total current assets | $2.27B | $1.37B | $1.22B | $693.8M | $954.4M |
| Property, plant and equipment | $55.4M | $61.0M | $87.1M | $72.6M | $52.6M |
| Goodwill | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M |
| Intangible assets | $388.8M | $118.8M | $379.5M | $705.9M | $724.8M |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B |
| Accounts payable | $45.5M | $17.3M | $6.04M | $27.3M | $23.0M |
| Short-term debt | $286.6M | – | – | – | $149.5M |
| Total current liabilities | $968.4M | $581.0M | $603.1M | $406.2M | $509.3M |
| Long-term debt | – | $285.4M | $284.2M | $571.7M | $281.9M |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B |
| Shareholders' equity | -$205.3M | -$1.10B | -$818.6M | -$347.1M | $1.44M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M |
| Capital expenditures | $8.86M | $6.50M | $28.4M | $32.0M | $28.2M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M |
| Depreciation and amortization | $38.8M | $75.7M | $236.6M | $128.8M | $64.1M |
| Stock-based compensation | $74.5M | $74.6M | $101.6M | $110.3M | $103.5M |
| Investing cash flow | -$862.0M | $44.2M | -$176.7M | $290.2M | $219.2M |
| Financing cash flow | $331.1M | $255.9M | $646.4M | $168.0M | $20.9M |
| Net change in cash | $203.0M | $185.0M | $314.4M | $98.7M | -$19.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.3% | 9.2% | 10.8% | 15.8% | 19.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 83.5M | +4.1% | SEC |
| Jul 29, 2026 | 83.5M | +5.1% | SEC |
| May 5, 2026 | 8.29M | −89.5% | SEC |
| Feb 18, 2026 | 82.8M | +5.0% | SEC |
| Nov 3, 2025 | 80.3M | +4.1% | SEC |
| Aug 5, 2025 | 79.4M | +3.3% | SEC |
| May 4, 2025 | 79.3M | +3.3% | SEC |
| Feb 25, 2025 | 78.9M | +3.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.